Regenerative Therapy

“Reversal of type 1 diabetes via islet beta cell regeneration following immune modulation by cord blood-derived multipotent stem cells.”
Zhao y. et al 2012 BMC Med. 10;10(1):3
“Stem Cell Educator therapy can markedly improve C-peptide levels, reduce the median glycated hemoglobin A1C (HbA1C) values, and decrease the median daily dose of insulin in patients with some residual beta cell function (n = 6) and patients with no residual pancreatic islet beta cell function (n = 6). Treatment …

BrainStorm Announces Clinical Data Supporting Safety and Efficacy of NurOwn™ Based on Initial ALS Patient Results
The ALS Phase I/II human clinical trial is being performed at Hadassah Medical Center in Israel in collaboration with BrainStorm and is utilizing BrainStorm’s NurOwn™ technology for growing and modifying autologous adult human stem cells to treat ALS, often referred to as Lou Gehrig’s Disease. The study is headed by Prof. Karussis, M.D., Ph.D
http://www.brainstorm-cell.com/Index.asp?ArticleID=260&CategoryID=76&Page=1

New clinical study to treat hearing loss by cord blood stem cells has been approved by the FDA:
“Safety of Autologous Human Umbilical Cord Blood Mononuclear Fraction to Treat Acquired Hearing Loss in Children”
Acquired sensorineural hearing loss i children will be treated with autologous cord blood cells. The primary objective of this study is to determine the safety of autologous hUCB infusion in children with acquired hearing loss. The secondary objective is to determine if functional, physiologic and anatomic outcomes …

Reversal of type 1 diabetes via islet beta cell regeneration following immune modulation by cord blood-derived multipotent stem cells
Yong Zhao, Zhaoshun Jiang, Tingbao Zhao, Mingliang Ye, Chengjin Hu, Zhaohui Yin, Heng Li, Ye Zhang, Yalin Diao, Yunxiang Li, Yingjian Chen, Xiaoming Sun, Mary Beth Fisk, Randal Skidgel, Mark Holterman, Bellur Prabhakar and Theodore Mazzon
BMC Medicine 2012, 10:3  http://www.biomedcentral.com/1741-7015/10/3/abstract
“A procedure for Stem Cell Educator therapy in which a patient’s blood is circulated through a closed-loop system that separate lymphocytes from the whole blood and briefly co-cultures them with adherent CB-SCs before returning them …

Outcome of unrelated umbilical cord blood transplantation in 88 patients with primary immunodeficiency in Japan.
Morio T, Atsuta Y, Tomizawa D, Nagamura-Inoue T, Kato K, Ariga T, Kawa K, Koike K, Tauchi H, Kajiwara M, Hara T, Kato S; Japanese Cord Blood Bank Network.
Department of Paediatrics and Developmental Biology, Tokyo Medical and Dental University Graduate School of Medical and Dental Sciences, Tokyo, Japan.
“Umbilical cord blood transplantation (UCBT) performed in 88 patients with primary immunodeficiency (PID) between …

Retinal Degenerative Diseases – Review
 The retina is converting light signals into neural signals, which are then transmitted to the brain.
The retina is located in the inner surface of the eye and is part of the central nervous system (CNS).
Any defects involved in photoreceptors and transmission in the retina will lead to visual impairment. Currently, retinal degenerative diseases which involve neuron-cells death are the major causes of blindness in the western world.
 
Age-related macular degeneration (AMD)
Among the …

“Safety and feasibility of autologous bone marrow cellular therapy in relapsing-progressive multiple sclerosis.”
Clin Pharmacol Ther. 2010 Jun;87(6):679-85
Rice CM et al.
SourceInstitute of Clinical Neurosciences, University of Bristol, Frenchay Hospital, Bristol, UK.
“In this phase I study, we assessed the safety and feasibility of intravenous, autologous bone marrow (BM) cell therapy, without immunosuppressive preconditioning, in six patients with clinically definite, relapsing-progressive multiple sclerosis (MS)”
“The lack of serious adverse effects and the suggestion of a beneficial effect in this …

Two clinical studies testing autologous cord blood infusion for treatment of children with cerebral palsy, now recruiting patients (November 2011):
1. “Safety and Effectiveness of Cord Blood Stem Cell Infusion for the Treatment of Cerebral Palsy in Children”
http://www.clinicaltrials.gov/ct2/show/NCT01072370?term=cerebral+palsy&rank=1

Medical College of Georgia
 

Augusta, Georgia, United States

2. “A Randomized Study of Autologous Umbilical Cord Blood Reinfusion in Children With Cerebral Palsy”
http://www.clinicaltrials.gov/ct2/show/NCT01147653?term=cerebral+palsy&rank=5

Duke University Medical Center
 

Durham, North Carolina, United States

The randomized, placebo-controlled Phase 2 trial compared the safety and efficacy of three doses of Revascor™ on top of maximal approved therapies versus maximal therapies alone in the patients, all with moderate-to-severe congestive heart failure.
Mesoblast Limited  announced positive Phase 2 heart failure trial results of its allogeneic, or off-the-shelf, adult stem cell product Revascor™ (mesenchymal stem cells) after all patients had completed a minimum follow-up of 12 months.
Treatment pooled across all doses in 45 patients …

November 14 2011 Geron said it would stop enrolling patients in its study of a stem cell-based treatment for spinal cord injury, after treating four patients.
Sep tember 2010 Phase I trial to evaluate GRNOPC1 in patients with  grade A subacute thoracic spinal cord injuries. The primary study endpoint is safety, but additional secondary endpoints will assess efficacy of the treatment in terms of improved neuromuscular control or sensation in the trunk or lower extremities.
GRNOPC1 is Geron’s cell product …